Replies to post #470637 on NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

There’s always a buyout price.

But I’m not sure the trial result was enough to convince a buyer to pay $15 or $20 billion at this stage.

I’m not in biotech, but my impression was the results are “approvable” but not necessarily WOW. Hope I’m dead wrong on that point - I’m sure you’ll let me know.

[Evaluate]

you wrote:

Suddenly we are not worthy of a buyout after meeting all endpoints?

The presentation yesterday seemed to indicate that the Primary Endpoint and the " first secondary endpoint" were met, but not that "all of the endpoints were met". Still great news. IMO.
See:
https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/GB
includes:
E.5 End points
E.5.1 Primary end point(s)
The primary endpoint of this study is overall survival (OS) compared between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma.
E.5.1.1 Timepoint(s) of evaluation of this end point
October 2020
E.5.2 Secondary end point(s)
The first secondary endpoint is overall survival (OS) compared between patients randomized to placebo who received DCVax-L treatment following disease recurrence, and control patients from comparable, contemporaneous clinical trials, in patients with recurrent GBM.

The second secondary endpoint, confirmed progression-free survival (cPFS), is confirmed disease progression (cPD) compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.

The third secondary endpoint, PFS, is progression-free survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.

The fourth secondary objective, OS, is overall survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.

The fifth secondary objective is tumor response compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.